SCHEMBL21986808

SCHEMBL21986808

COC(=O)c1c(Cl)ccc2nn(C3CCCCO3)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 6/20 0.39
▸ ATR Q13535 1/20 0.36
▸ TAS1R3 Q7RTX0 2/20 0.34
▸ TAS1R1 Q7RTX1 2/20 0.34
▸ TAS1R2 Q8TE23 2/20 0.34
▸ YTHDC1 Q96MU7 1/20 0.34
▸ POLB P06746 2/20 0.33
▸ MAPT P10636 3/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ HPGD P15428 3/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ LMNA P02545 3/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ABL1 P00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21986700 0.89 ATR (0.36) SLC6A3ATRPOLBMAPTNPSR1
SCHEMBL21986791 0.88 ALDH1A1 (0.36) ATRMAPTNPSR1HPGDLMNA
SCHEMBL21986713 0.79 SLC6A3 (0.38) SLC6A3ATRTAS1R3TAS1R1TAS1R2
SCHEMBL21986898 0.78 SLC6A3 (0.39) SLC6A3ATRTAS1R3TAS1R1TAS1R2
SCHEMBL21986849 0.72 FGFR1 (0.34) ATRMAPTNPSR1HPGDNPC1
SCHEMBL31667725 0.71 LMNA (0.42) SLC6A3YTHDC1HPGDNPC1RAB9A
SCHEMBL21986817 0.70 CYP4F2 (0.35) ATRNPC1RAB9AALDH1A1MEN1
SCHEMBL21986801 0.70 CYP4F2 (0.33) ATRYTHDC1NPC1RAB9AMEN1
SCHEMBL21986745 0.70 ATR (0.33) ATRMAPTNPSR1HPGDALDH1A1
SCHEMBL21986911 0.69 CYP4F2 (0.38) ATRPOLBMAPTNPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660003-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-01-24 — — EP disclosed
US-11713311-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-01 — — US disclosed
US-20220388995-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-12-08 — — US disclosed
US-11230541-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-25 — — US disclosed
US-20200231579-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed
EP-3660003-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-06-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230541-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885ATR 3544/4885TAS1R3 1680/4885
US-20200231579-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885ATR 3544/4885TAS1R3 1680/4885
US-11713311-B2 Heterocyclic compound GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885ATR 3544/4885TAS1R3 1680/4885
US-20220388995-A1 HETEROCYCLIC COMPOUND GRIN1, GRIN2A, GRIN2B SLC6A3 721/4885ATR 3544/4885TAS1R3 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback